Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.

NCT07586904 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin Cancer)

Interventions

DRUG: Cadonilimab and Recombinant Human Interferon α1b Combination Therapy

Sponsor

Xijing Hospital